Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Treasury Shares (2020 - 2025)

Insight Molecular Diagnostics' Treasury Shares history spans 6 years, with the latest figure at $917000.0 for Q3 2025.

  • For Q3 2025, Treasury Shares changed N/A year-over-year to $917000.0; the TTM value through Sep 2025 reached $917000.0, changed N/A, while the annual FY2024 figure was $100000.0, 1900.0% up from the prior year.
  • Treasury Shares for Q3 2025 was $917000.0 at Insight Molecular Diagnostics, up from $792000.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $1.5 million in Q3 2022 and bottomed at $5000.0 in Q3 2023.
  • The 5-year median for Treasury Shares is $161000.0 (2021), against an average of $359294.1.
  • The largest annual shift saw Treasury Shares plummeted 99.66% in 2023 before it skyrocketed 15020.0% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $121000.0 in 2021, then plummeted by 81.82% to $22000.0 in 2022, then plummeted by 77.27% to $5000.0 in 2023, then soared by 1900.0% to $100000.0 in 2024, then surged by 817.0% to $917000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Treasury Shares are $917000.0 (Q3 2025), $792000.0 (Q2 2025), and $756000.0 (Q1 2025).